InflaRx presents pre‑clinical data showing izicopan protects kidneys in hamster injury models
InflaRx N.V. disclosed results from two hamster studies in which oral izicopan lowered markers of kidney damage and improved tissue scores. In the ischemia‑reperfusion model, a single 100 mg/kg dose given four hours before surgery cut creatinine and BUN levels versus control. In the unilateral ureteral obstruction model, the drug was given a few hours before the procedure and then each day for two weeks, also reducing BUN and enhancing histopathology. The company said the findings support further development of izicopan for ANCA‑associated vasculitis and other complement‑driven renal diseases.
Why it matters
The data provide the first pre‑clinical evidence that izicopan can mitigate acute and progressive kidney injury, which may de‑risk future clinical trials and attract partnership or funding. Investors should watch for updates on the planned renal‑indication program, as successful translation could expand the company’s pipeline beyond its current focus.
Key facts
- 1InflaRx presented the pre‑clinical results at the American Society of Nephrology’s Kidney Week 2026 in Denver. stocktitan.net
- 2In the ischemia‑reperfusion injury model, a single oral dose of 100 mg/kg given four hours before surgery significantly lowered plasma creatinine and blood urea nitrogen (BUN) versus vehicle (p < 0.001 for both). stocktitan.net
- 3In the unilateral ureteral obstruction model, izicopan was administered orally a few hours before surgery and then once daily for 14 days, leading to a significant reduction in BUN (p < 0.001) and improvement in total H&E histopathological score (p < 0.05) compared with vehicle. stocktitan.net
- 4The company plans to develop izicopan for ANCA‑associated vasculitis and additional renal indications. stocktitan.net
- 5Izicopan is a second‑generation oral C5aR1 antagonist that shows reduced potential for CYP3A4/5 time‑dependent inhibition relative to avacopan. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.